Interleukin 17A: Toward a new understanding of psoriasis pathogenesis

Journal of the American Academy of Dermatology

Volumn 71, Issue 1, 2014, Pages 141-150

  Lynde, Charles W ^a   Poulin, Yves ^b   Vender, Ronald ^c   Bourcier, Marc ^d   Khalil, Sam ^e  

^a Lynderm Research Inc Canada   (Canada)

^b Centre de Recherche Dermatologique du Quebec Metropolitain   (Canada)

^c Dermatrials Research   (Canada)

^d Durondel CP Inc   (Canada)

^e Novartis Pharmaceuticals   (Canada)

Author keywords

cytokines; interleukin 17A; interleukin 23; keratinocytes; pathogenesis; psoriasis; T helper 1 cells; T helper 17 cells

Indexed keywords

ETANERCEPT; INTERLEUKIN 12P35; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 23; INTERLEUKIN 6; IXEKIZUMAB; SECUKINUMAB; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ARTICLE; CD8+ T LYMPHOCYTE; HUMAN; INNATE IMMUNITY; KERATINOCYTE; MAST CELL; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; SKIN BIOPSY; TH1 CELL; TH17 CELL;

CYTOKINES; INTERLEUKIN-17A; INTERLEUKIN-23; KERATINOCYTES; PATHOGENESIS; PSORIASIS; T-HELPER 17 CELLS; T-HELPER 1 CELLS;

ANTIBODIES, MONOCLONAL; DENDRITIC CELLS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-17; MODELS, IMMUNOLOGICAL; PSORIASIS; TH17 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84903307484     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2013.12.036     Document Type: Review

References (89)

1. J.M. Gelfand, R. Weinstein, S.B. Porter, A.L. Neimann, J.A. Berlin, and D.J. Margolis Prevalence and treatment of psoriasis in the United Kingdom: a population-based study Arch Dermatol 141 2005 1537 1541
2. S.K. Kurd, and J.M. Gelfand The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004 J Am Acad Dermatol 60 2009 218 224
3. P.L. Mattei, K.C. Corey, and A.B. Kimball Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies J Eur Acad Dermatol Venereol 28 2014 333 337
4. F.O. Nestle, D.H. Kaplan, and J. Barker Psoriasis N Engl J Med 361 2009 496 509
5. E.F. Wagner, H.B. Schonthaler, J. Guinea-Viniegra, and E. Tschachler Psoriasis: what have we learned from mouse models Nat Rev Rheumatol 6 2010 704 714
6. S.L. Gottlieb, P. Gilleaudeau, R. Johnson, L. Estes, T.G. Woodworth, and A.B. Gottlieb et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis Nat Med 1 1995 442 447
7. J.R. Bjerke Subpopulations of mononuclear cells in lesions of psoriasis, lichen planus and discoid lupus erythematosus studied using monoclonal antibodies Acta Derm Venereol 62 1982 477 483
8. H. Hammar, S.Q. Gu, A. Johannesson, K.G. Sundkvist, and P. Biberfeld Subpopulations of mononuclear cells in microscopic lesions of psoriatic patients: selective accumulation of suppressor/cytotoxic T cells in epidermis during the evolution of the lesion J Invest Dermatol 83 1984 416 420
9. W. Mueller, and B. Herrmann Cyclosporin A for psoriasis N Engl J Med 301 1979 555
10. C.N. Ellis, D.C. Gorsulowsky, T.A. Hamilton, J.K. Billings, M.D. Brown, and J.D. Headington et al. Cyclosporine improves psoriasis in a double-blind study JAMA 256 1986 3110 3116
11. B.V. Jegasothy, C.D. Ackerman, S. Todo, J.J. Fung, K. Abu-Elmagd, and T.E. Starzl Tacrolimus (FK 506)-A new therapeutic agent for severe recalcitrant psoriasis Arch Dermatol 128 1992 781 785
12. T.R. Mosmann, H. Cherwinski, M.W. Bond, M.A. Giedlin, and R.L. Coffman Two types of murine helper T cell clone, I: definition according to profiles of lymphokine activities and secreted proteins J Immunol 136 1986 2348 2357
13. R. Manetti, P. Parronchi, M.G. Giudizi, M.P. Piccinni, E. Maggi, and G. Trinchieri et al. Natural killer cell stimulatory factor (interleukin-12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits development of IL-4-producing Th cells J Exp Med 177 1993 1199 1204
14. M. Kobayashi, L. Fitz, M. Ryan, R.M. Hewick, S.C. Clark, and S. Chan et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biological effects on human lymphocytes J Exp Med 170 1989 827 845
15. N. Yawalkar, S. Karlen, R. Hunger, C.U. Brand, and L.R. Braathen Expression of interleukin-12 is increased in psoriatic skin J Invest Dermatol 111 1998 1053 1057
16. T. Biedermann, M. Röcken, and J.M. Carballido TH1 and TH2 lymphocyte development and regulation of TH cell-mediated immune responses of the skin J Investig Dermatol Symp Proc 9 2004 5 14
17. R. Lande, J. Gregorio, V. Facchinetti, B. Chatterjee, Y.H. Wang, and B. Homey et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide Nature 449 2007 564 569
18. P.J. Mease, B.S. Goffe, J. Metz, A. VanderStoep, B. Finck, and D.J. Burge Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial Lancet 356 2000 385 390
19. B. Oppmann, R. Lesley, B. Blom, J.C. Timans, Y. Xu, and B. Hunte et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12 Immunity 13 2000 715 725
20. D.J. Cua, J. Sherlock, Y. Chen, C.A. Murphy, B. Joyce, and B. Seymour et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain Nature 421 2003 744 748
21. C.A. Murphy, C.L. Langrish, Y. Chen, W. Blumenschein, T. McClanahan, and R.A. Kastelein et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation J Exp Med 198 2003 1951 1957
22. C.L. Langrish, Y. Chen, W.M. Blumenschein, J. Mattson, B. Barsham, and J.D. Sedgwick et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation J Exp Med 201 2005 233 240
23. E. Lee, W.L. Trepicchio, L. Oestreicher, D. Pittman, F. Wang, and F. Chamian et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris J Exp Med 199 2004 125 130
24. G. Piskin, R.M. Sylva-Steenland, J.D. Bos, and M.B. Teunissen In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin J Immunol 176 2006 1908 1915
25. J. Luo, S.J. Wu, E.R. Lacy, Y. Orlovsky, A. Baker, and A. Teplyakov et al. Structural basis for the dual recognition of IL-12 and IL-23 by ustekinumab J Mol Biol 402 2010 797 812
26. J.M. Benson, C.W. Sachs, G. Treacy, H. Zhou, C.E. Pendley, and C.M. Brodmerkel et al. Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab Nat Biotechnol 29 2011 615 624
27. S. Aggarwal, N. Ghilardi, M.H. Xie, F.J. de Sauvage, and A.L. Gurney Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17 J Biol Chem 278 2003 1910 1914
28. + effector T cells develop a lineage distinct from the T helper type 1 and 2 lineages Nat Immunol 6 2005 1123 1132
29. H. Park, Z. Li, X.O. Yang, S.H. Chang, R. Nurieva, and Y.H. Wang et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17 Nat Immunol 6 2005 1133 1141
30. S. Leung, X. Liu, L. Fang, X. Chen, T. Guo, and J. Zhang The cytokine milieu in the interplay of pathogenic Th1/Th17 cells and regulatory T cells in autoimmune disease Cell Mol Immunol 7 2010 182 189
31. P. Miossec, T. Korn, and V.K. Kuchroo Interleukin-17 and type 17 helper T cells N Engl J Med 361 2009 888 898
32. J. Zhu, H. Yamane, and W.E. Paul Differentiation of effector CD4 T cell populations Annu Rev Immunol 28 2010 445 489
33. N.J. Wilson, K. Boniface, J.R. Chan, B.S. McKenzie, W.M. Blumenschein, and J.D. Mattson et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells Nat Immunol 8 2007 950 957
34. E. Segura, M. Touzot, A. Bohineust, A. Cappuccio, G. Chiocchia, and A. Hosmalin et al. Human inflammatory dendritic cells induce Th17 cell differentiation Immunity 38 2013 336 348
35. + T cells Arthritis Res Ther 11 2009 257
36. S. Kagami, H.L. Rizzo, J.J. Lee, Y. Koguchi, and A. Blauvelt Circulating Th17, Th22, and Th1 cells are increased in psoriasis J Invest Dermatol 130 2010 1373 1383
37. 1 Expert Rev Dermatol 2 2007 69 78
38. E. Fitch, E. Harper, I. Skorcheva, S.E. Kurtz, and A. Blauvelt Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines Curr Rheumatol Rep 9 2007 461 467
39. M.A. Lowes, T. Kikuchi, J. Fuentes-Duculan, I. Cardinale, L.C. Zaba, and A.S. Haider et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 cells J Invest Dermatol 128 2008 1207 1211
40. S. Kagami, H.L. Rizzo, S.E. Kurtz, L.S. Miller, and A. Blauvelt IL-23 and IL-17A, but not IL-12 and IL-22, are required for optimal skin host defense against Candida albicans J Immunol 185 2010 5453 5462
41. H.L. Rizzo, S. Kagami, K.G. Phillips, S.E. Kurtz, S.L. Jacques, and A. Blauvelt IL-23-mediated psoriasis-like epidermal hyperplasia is dependent on IL-17A J Immunol 186 2011 1495 1502
42. S. Tian, J.G. Krueger, K. Li, A. Jabbari, C. Brodmerkel, and M.A. Lowes et al. Meta-analysis derived (MAD) transcriptome of psoriasis defines the "core" pathogenesis of disease PLoS One 7 2012 e44274
43. P. Di Meglio, F. Villanova, L. Napolitano, I. Tosi, M.T. Barbberio, and R.K. Mak et al. The IL23R A/Gln381 allele promotes IL-23 unresponsiveness in human memory T-helper 17 cells and impairs Th17 responses in psoriasis patients J Invest Dermatol 133 2013 2381 2389
44. R. Pappu, V. Ramirez-Carrozzi, N. Ota, W. Ouyang, and Y. Hu The IL-17 family cytokines in immunity and disease J Clin Immunol 30 2010 185 195
45. Y. Iwakura, H. Ishigame, S. Saijo, and S. Nakae Functional specialization of interleukin-17 family members Immunity 34 2011 149 162
46. J.K. Kolls, and A. Lindén Interleukin-17 family members and inflammation Immunity 21 2004 467 476
47. S.L. Gaffen Structure and signaling in the IL-17 receptor family Nat Rev Immunol 9 2009 556 567
48. V. Ramirez-Carrozzi, A. Sambandam, E. Luis, Z. Lin, S. Jeet, and J. Lesch et al. IL-17C regulates the innate immune function of epithelial cells in an autocrine manner Nat Immunol 12 2011 1159 1166
49. A. Johnston, Y. Fritz, S.M. Dawes, D. Diaconu, P.M. Al-Attar, and A.M. Guzman Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation J Immunol 190 2013 2252 2262
50. C. Johansen, P.A. Usher, R.B. Kjellerup, D. Lundsgaard, L. Iversen, and K. Kragballe Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin Br J Dermatol 160 2009 319 324
51. R.M. Onishi, and S.L. Gaffen Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease Immunology 129 2010 311 321
52. A.M. Lin, C.J. Rubin, R. Khandpur, J.Y. Wang, M. Riblett, and S. Yalavarthi et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis J Immunol 187 2011 490 500
53. C.T. Weaver, R.D. Hatton, P.R. Mangan, and L.E. Harrington IL-17 family cytokines and the expanding diversity of effector T cell lineages Annu Rev Immunol 25 2007 821 852
54. P.C.M. Res, G. Piskin, O.J. de Boer, C.M. van der Loos, P. Teeling, and J.D. Bos et al. Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis PloS One 5 2010 e14108
55. + T cell trafficking and development by IFN-γ: mechanism and pathological relevance in psoriasis J Immunol 181 2008 4733 4741
56. J. Li, X. Chen, Z. Liu, Q. Yue, and H. Liu Expression of Th17 cytokines in skin lesions of patients with psoriasis J Huazhong Univ Sci Technolog Med Sci 27 2007 330 332
57. E.G. Harper, C. Guo, H. Rizzo, J.V. Lillis, S.E. Kurtz, and I. Skorcheva et al. Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis J Invest Dermatol 129 2009 2175 2183
58. + T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines J Leukoc Biol 86 2009 435 443
59. + T cells in the lesional skin of atopic dermatitis and psoriasis patients are an important source of IFN-γ, IL-13, IL-17, and IL-22 J Invest Dermatol 133 2013 973 979
60. K.E. Nograles, L.C. Zaba, E. Guttman-Yassky, J. Fuentes-Duculan, M. Suárez-Fariñas, and I. Cardinale et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways Br J Dermatol 159 2008 1092 1102
61. B. Homey, M.C. Dieu-Nosjen, A. Wiesenborn, C. Massacrier, J.J. Pin, and E. Oldham et al. Up-regulation of macrophage inflammatory protein-3 alpha/CCL-20 and CC chemokine receptor 6 in psoriasis J Immunol 164 2000 6621 6632
62. A. Chiricozzi, E. Guttman-Yassky, M. Suárez-Fariñas, K.E. Nograles, S. Tian, and I. Cardinale et al. Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis J Invest Dermatol 131 2011 677 687
63. S.C. Liang, X.Y. Tan, D.P. Luxenberg, R. Karim, K. Dunussi-Joannopoulos, and M. Collins et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides J Exp Med 203 2006 2271 2279
64. X. Shi, L. Jin, E. Dang, T. Chang, Z. Feng, and Y. Liu et al. IL-17A up-regulates keratin 17 expression in keratinocytes through STAT1- and STAT3-dependent mechanisms J Invest Dermatol 131 2011 2401 2408
65. D. Gutowska-Owsiak, A.L. Schaupp, M. Salimi, T.A. Selvakumar, T. McPherson, and S. Taylor et al. IL-17 down-regulates filaggrin and affects keratinocyte expression of genes associated with cellular adhesion Exp Dermatol 21 2012 104 110
66. M.A. Lowes, F. Chamian, M.V. Abello, J. Fuentes-Duculan, S.L. Lin, and R. Nussbaum et al. Increase in TNF-α and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a) Proc Natl Acad Sci USA 102 2005 19057 19062
67. S. Lisby, A. Faurschou, and R. Gniadecki The autocrine TNFα signaling loop in keratinocytes requires atypical PKC species and NF-κB activation but is independent of cholesterol-enriched membrane microdomains Biochem Pharmacol 73 2007 526 533
68. C. Johansen, A.T. Funding, K. Otkjaer, K. Kragballe, U.B. Jensen, and M. Madsen et al. Protein expression of TNF-α in psoriatic skin is regulated at a posttranscriptional level by MAPK-activated protein kinase 2 J Immunol 176 2006 1431 1438
69. + Treg cell accumulation and correlated with psoriasis disease severity Clin Immunol 135 2010 108 117
70. O. Arican, M. Aral, S. Sasmaz, and P. Ciragil Serum levels of TNF-α, IFN-γ, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity Mediators Inflamm 2005 2005 273 279
71. H. Takahashi, H. Tsuji, Y. Hashimoto, A. Ishida-Yamamoto, and H. Iizuka Serum cytokines and growth factor levels in Japanese patients with psoriasis Clin Exp Dermatol 35 2010 645 649
72. S.B. Yilmaz, N. Cicek, M. Coskun, O. Yegin, and E. Alpsoy Serum and tissue levels of IL-17 in different clinical subtypes of psoriasis Arch Dermatol Res 304 2012 465 469
73. M. Caproni, E. Antiga, L. Melani, W. Volpi, E. Del Bianco, and P. Fabbri Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis J Clin Immunol 29 2009 210 214
74. S. Coimbra, H. Oliveira, F. Reis, L. Belo, S. Rocha, and A. Quintanilha et al. Interleukin (IL)-22, IL-17, IL-23, IL-8, vascular endothelial growth factor and tumor necrosis factor-α levels in patients with psoriasis before, during and after psoralen-ultraviolet A and narrowband ultraviolet B therapy Br J Dermatol 163 2010 1282 1290
75. L.C. Zaba, M. Suárez-Fariñas, J. Fuentes-Duculan, K.E. Nograles, E. Guttman-Yassky, and I. Cardinale et al. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes J Allergy Clin Immunol 124 2009 1022 1110 e1-395
76. L.C. Zaba, I. Cardinale, P. Gilleaudeau, M. Sullivan-Whalen, M. Suárez-Fariñas, and J. Fuentes-Duculan et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses J Exp Med 204 2007 3183 3194
77. A. Puel, S. Cypowyj, J. Bustamante, J.F. Wright, L. Liu, and H.K. Lim et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity Science 332 2011 65 68
78. K. Kisand, A.S. Bøe Wolff, K.T. Podkrajsek, L. Tserel, M. Link, and K.V. Kisand et al. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines J Exp Med 207 2010 299 308
79. A. Puel, R. Döffinger, A. Natividad, M. Chrabieh, G. Barcenas-Morales, and C. Picard et al. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I J Exp Med 207 2010 291 297
80. F.L. van de Veerdonk, T.S. Plantinga, A. Hoischen, S.P. Smeekens, L.A. Joosten, and C. Gilsssen et al. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis N Engl J Med 365 2011 54 61
81. M.O. Chandesris, I. Melki, A. Natividad, A. Puel, C. Fieschi, and L. Yun et al. Autosomal dominant STAT3 deficiency and hyper-IgE syndrome: molecular, cellular, and clinical features from a French national survey Medicine (Baltimore) 91 2012 e1 e19
82. B. Boisson, C. Wang, V. Pedergnana, L. Wu, S. Cypowyj, and M. Rybojad et al. An ACT1 mutation selectively abolishes interleukin-17 responses in humans with chronic mucocutaneous candidiasis Immunity 39 2013 676 686
83. A. Drewniak, R.P. Gazendam, A.T. Tool, M. van Houdt, M.H. Jansen, and J.L. van Hamme et al. Invasive fungal infection and impaired neutrophil killing in human CARD9 deficiency Blood 121 2013 2385 2392
84. K.A. Papp, R.G. Langley, B. Sigurgeirsson, M. Abe, D.R. Baker, and P. Konno et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study Br J Dermatol 168 2013 412 421
85. P. Rich, B. Sigurgeirsson, D. Thaci, J.P. Ortonne, C. Paul, and R.E. Schopf et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study Br J Dermatol 168 2013 402 411
86. C. Leonardi, R. Matheson, C. Zachariae, G. Cameron, L. Li, and E. Edson-Heredia et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis N Engl J Med 366 2012 1190 1199
87. K. Papp, C. Leonardi, A. Menter, J.P. Ortonne, J.G. Krueger, and G. Kricorian et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis N Engl J Med 366 2012 1181 1189
88. W. Hueber, D.D. Patel, T. Dryja, A.M. Wright, I. Koroleva, and I. Bruin et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis Sci Transl Med 2 2010 52ra72
89. J.G. Krueger, S. Fretzin, M. Suárez-Fariñas, P.A. Haslett, K.M. Phipps, and G.S. Cameron et al. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis J Allergy Clin Immunol 130 2012 145 154.e9